Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PBC-AIH overlap syndrome is an autoimmune liver disease between AIH (autoimmune hepatitis) and PBC (primary biliary cirrhosis). To investigate the characteristic of the PBC-AIH overlap syndrome, we have conducted a retros-pective study of 12 diagnosed overlap syndrome patients and compared them with typical PBC and AIH on the basis of clinical, biochemical, serological and histopathological findings. METHODS Patients A total of 52 patients referred to our hospital between January 1998 and January 2004 were diagnosed with autoimmune liver disease. Of the 52 patients, 12 patients suffered from PBC-AIH overlap syndrome, 20 was typical AIH, 20 was typical PBC. PBC-AIH overlap syndrome was strictly defined according to PBC diagnosis published by the American Association for the Study of Liver Disease in 20001 and the Criteria for Diagnosis of AIH revised by the International AIH Group in 1998.2 Biochemical and immunoserological tests Information on each patient including symptoms, signs, clinical findings and data from laboratory or other diagnostic investigations were obtained both at the initial and follow-up visits. Blood samples were obtained for measurements of bilirubin, alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transminase (ALT), glutamyine transpe-ptidase (GGT) and immunoglobulin quantification. IgG and IgM levels were measured by standard techniques, and SMA (anti-smooth muscle antibody), ANA (anti nuclear antibody), LKM (anti liver-kidney antibody), AMA (anti mitochondrial antibody) and AMA M2 were measured by immunofluorescence assays. Histopathologic assessment Liver biopsies were performed before treatment in 52 patients, and the histologic features were evaluated by a single experienced pathologist. The severity of the necroinflammatory process was graded on a scale according to the METAVIR cooperative group criteria.3 Therapy Of the 12 overlap syndrome patients, 3 patients were treated with ursodeoxycholic acid (UDCA) monotherapy (13 — 15 mg · kg−1 · d−1, divided into three separate doses) alone; 3 were treated with prednisone alone at a starting dose of 50 mg/d and then the dosage was reduced until remission was achieved (the indication for prednisone therapy must be individualized); The other six patients were treated with prednisone in combination with UDCA. Statistical analysis Quantitative analysis has been represented by mean ± standard error (SE). Statistical analysis was performed with the Student's t test. Counting analysis has been represented by case number and percentage, statistical analysis was performed by means of χ2 test. P<0.05 is considered significantly different. RESULTS Clinical features Table 1 gives the age and the sex distribution of the three groups of patient, the strong female predominance was found. There was no significant difference among three groups on age, sex proportion and positive percentage of clinical symptoms.Table 1: Age and the sex distribution and laboratory features of the three patient groups at the the time of diagnosis (mean ± SE)Laboratory findings The overlap group showed characteristics of both AIH and PBC. There was a significant difference between the overlap syndrome and PBC groups on ALT, AST, IgG and γ-globulin, and between the overlap syndrome and AIH groups on GGT, ALP and IgM as shown in Table 1. Immunoserological findings at presentation are summarized in Table 2.Table 2: Autoantibody distribution of the three groups at the time of diagnosis (number,%)Histopathology The overlap syndrome showed combined histo-pathological features of both the diseases. The comparison of histopathological findings in overlap syndrome with PBC and AIH are summarized in Table 3.Table 3: Histopathological features of hepatitis and bile duct destruction of the three groups at the time of diagnosis (n,%)Therapy Prednisone treatment was given to 3 of the 12 PBC-AIH overlap syndrome patients, the patients achieved incomplete remission, the serum amino- transferase remained above twice the normal, GGT and ALP did not decrease significantly. After 3-month combination of UDCA and prednisone, the patients entered completely remission after 6 months and withdrew from the treatment within 6 week after 1 year of combined therapy. In 3 of the 12 PBC/AIH patients who received UDCA monotherapy, biochemical features of cholestasis decreased significantly, but ALT and AST levels tended to be higher. Three months later prednisone was added, then the patients achieved remission after six months. In 6 of the the 12 overlap syndrome patients combination of UDCA and prednisone were given. All the 6 patients were asymptomatic, or symptoms or laboratory tests improved. They entered remission within 6 months. Prednisone was successfully stopped over a 6-week period after 1 year of combined therapy. Three patients had a sustained remission after a follow-up of 36 months. Three patients relapsed at 6 months after stopping prednisone treatment, then prednisone was
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Lohse, A. W., zum Büschenfelde, K.-H. M., Franz, B., Kanzler, S., Gerken, G., & Dienes, H.-P. (1999) · Hepatology · doi:10.1002/hep.510290409 · Cited by 278
Joshi, S., Cauch-Dudek, K., Wanless, I. R., Lindor, K. D., Jorgensen, R., Batts, K., & Heathcote, J. E. (2002) · Hepatology · doi:10.1053/jhep.2002.30902 · Cited by 174
Cited by
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555
“Treatment of PBC patients with features of AIH Several studies have demonstrated a positive response to immunosuppressive therapy in patients with overlapping features between PBC and AIH [22,61,62,73,109,111,112], but it has also been suggested that treatment solely with UDCA alone is sufficient [63].”
BackgroundInfluentialThe serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome
Muratori, P., Granito, A., Pappas, G., Pendino, G. M., Quarneti, C., Cicola, R., Menichella, R., Ferri, S., Cassani, F., Bianchi, F. B., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.126 · Cited by 125
Liu, F., Pan, Z. G., Ye, J., Xu, D., Guo, H., Li, G. P., Xu, K. S., Hou, X. H., & Song, Y. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12196 · Cited by 23
Zhang, H., Li, S., Yang, J., Zheng, Y., Wang, J., Lu, W., Zhou, Y., Yin, Q., Zhu, R., & Guo, C. (2015) · Gastroenterology Review · doi:10.5114/pg.2015.51187 · Cited by 17
“In some studies of PBC-AIH, the results of a therapy combining UDCA and corticosteroids were encouraging [9, 10], but there have been few local studies [11].”
Result
Metadata
- Authors
- WU, C.-H., WANG, Q.-H., TIAN, G.-S., XU, X.-Y., YU, Y.-Y., & WANG, G.-Q.
- Venue
- Chinese Medical Journal
- Published
- 2006-02
- Volume
- 119
- Issue
- 3
- Pages
- 238-241
- ISSN
- 0366-6999 (ISSN-L)
- OpenAlex
- W299313606
- Cited by
- 12
- References
- 3
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study. https://app.cochat.ai/papers/10.1097/00029330-200602010-00013
- The paper
- WU, C.-H., WANG, Q.-H., TIAN, G.-S., XU, X.-Y., YU, Y.-Y., & WANG, G.-Q. (2006). Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study. Chinese Medical Journal. https://doi.org/10.1097/00029330-200602010-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.